Effect of redox metabolic flux regulated by cancer metabolism on anticancer drug resistance

2019 Fiscal Year Final Research Report

• Project/Area Number: 17K15673
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Experimental pathology
• Research Institution: Nippon Medical School
• Principal Investigator: Ishino Kousuke 日本医科大学, 医学部, 講師 (60584878)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Keywords: 2-デオキシグルコース / 膵がん細胞株 / メトホルミン / がん代謝 / 併用投与 / 相乗効果 / 抗がん剤耐性 / 抗酸化代謝物

Outline of Final Research Achievements

Many cancer cells also exert resistance to the action of anti-cancer agents because they reprogram metabolism in a glycolytic-dominant manner and respond to adverse environments. The glucose analog 2-deoxyglucose (2DG) not only inhibits glycolysis and suppresses the growth of cancer cells, but also enhances the action of drugs such as anticancer agents. In the present study, we found that 2DG synergistically enhanced the action of cisplatin or metformin on pancreatic cancer cells. It was also found that the combination of 2DG and metabolite suppressed the action of 2DG on cells. It is expected that the cancer treatment will be further advanced by further understanding the action of 2DG.

Free Research Field

実験病理学

Academic Significance and Societal Importance of the Research Achievements

本研究は、がんが栄養の使い方を変化させてブドウ糖を多量に使うようになっている性質を利用して新しい薬の候補を調べた研究です。がん細胞がブドウ糖を使うのを防ぐ2DGという化合物を、抗がん剤などの薬（シスプラチンやメトホルミン）と一緒にがん細胞に加えると、薬の効き目が高くなることがわかりました。この飲み合わせが効果的な理由を調べることで、いろいろながんに効く薬を作るヒントを調べられる可能性があります。